spacer
home > ebr > winter 2018 > keeping it clean
PUBLICATIONS
European Biopharmaceutical Review

Keeping It Clean

Advanced therapy medicinal products (ATMPs) are for human use, often in the field of regenerative medicine. They can be stratified into one of the following three categories of product: gene therapy; somatic cell therapy; and tissue engineering and regenerative medicine.

Figures 1 and 2 provide an overview of the distribution of ATMPs currently in development or on the market according to clinical application (1). The sponsors of ATMPs differ widely from the classical, heavily regulated, pharmaceutical market (see Figure 3). Currently, roughly 75% of ATMPs are being developed within the non-commercial sector (universities, hospitals, institutes and so forth) – an aspect that adds unique and significant regulatory challenges when guaranteeing that such products comply with the strict requirements for biological medicinal products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andy Bailey is a virologist who has been actively involved in the pathogen safety of biopharmaceuticals for over 20 years. Originally a biochemist, Andy served for nine years at the MRC virology unit in Glasgow, Scotland. In 1995, he moved as Director of virus validation services to Q-One Biotech, and later to the pathogen safety group of Baxter Healthcare in Vienna, Austria. Since 2005, Andy has been a founder and Chief Executive Officer of ViruSure in Vienna, Austria, a company specialising in virus and prion safety testing of biopharmaceutical products. Over the last 22 years, Andy has presented at numerous regulatory agencies, either in support of products or as an invited speaker at expert workshops.
spacer
Andy Bailey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement